EXPLORING COX-1 AND COX-2 INHIBITION POTENTIAL OF AMBERBOA DIVARICATA AERIAL PARTS THROUGH IN-SILICO AND IN-VITRO STUDIES
Main Article Content
Keywords
anti-inflammatory, Amberboa divaricata, docking, inhibition, COX-1; COX-2
Abstract
Acute and chronic inflammatory illnesses continue to be one of the world's most serious public health issues. Although various medications are known to treat inflammatory illnesses, long-term treatment frequently results in severe side effects. This study aimed to identify the COX-1 and COX-2 inhibitory potential of Amberboa divaricata through in-silico and in-vitro studies. The extract was prepared using the ether:petroleum ether (1:2) and dried to obtain the residue which was further used for the assay. The assay was performed using the kit and the ligands (phytoconstituents) were docked against the COX-1 and COX-2 by docking studies. The assay showed an inhibition rate of 61.32% COX-2 and 59.01% (COX-1) at 100 µg/ml. The IC50 of the extract residue was 75.10 µg/ml (COX-1) and 70.76 µg/ml (COX-2). The docking studies revealed that only cynaropicrin and desacylcynaropicrin interacted with the active sites of the COX-1 and COX-2 owing to the hydrophilic binding nature of the proteins. Further isolation and preclinical studies is needed to identify the complete potential of the phytoconstituents and their effect on COX-1 and COX-2 targets.
References
2. Braunwald E, Fauci AS, Kasper DL, Hauser S, Longo D, Jameson L. Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw-Hill; 2001.
3. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002;360(9339):1071-3.
4. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Scand J Rheumatol. 1996;25(sup102):9-21.
5. Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. Eur J Pharmacol. 2004;500(1-3):427-39.
6. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s-110s.
7. Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem. 2002;9(10):1033-43.
8. Suleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclo-oxygenase inhibitors. Pharmacol Rep. 2007;59(3):247.
9. Rainsford KD. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med. 1999;107(6):27-35.
10. Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2–specific inhibitors. Am J Med. 2001;110(3):13-9.
11. Ibrahim M, Khan R, Malik A. Two new guaianolides from Amberboa ramosa. Nat Prod Commun. 2010;5(12):1934578X1000501204.
12. Bhattacharjee SK. Medicinal herbs and flowers. Jaipur: Avishkar Publishers; 2001.
13. Singh R, Mewara DK. Isolation and characterization of sesquiterpene lactones from the genus Amberboa. Int Res J Chem. 2018;23:01.
14. Mali SN, Chaudhari HK. Computational studies on imidazo[1,2-a]pyridine-3-carboxamide analogues as antimycobacterial agents. Open Pharm Sci J. 2018;5(1).
15. Lu C, Wu C, Ghoreishi D, et al. OPLS4: Improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput. 2021;17(7):4291-300.
16. Orlando BJ, Malkowski MG. Crystal structure of rofecoxib bound to human cyclooxygenase-2. Acta Crystallogr F Struct Biol Commun. 2016;72(10):772-6.
17. Rimon G, Sidhu RS, Lauver DA, et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci U S A. 2010;107(1):28-33.
18. Madhavi Sastry G, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221-34.
19. Al-Suwaidan IA, Alanazi AM, El-Azab AS, et al. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Bioorg Med Chem Lett. 2013;23(9):2601-5.
20. Shaikh MM, Patel AP, Patel SP, Chikhalia KH. Synthesis, in vitro COX-1/COX-2 inhibition testing and molecular docking study of novel 1,4-benzoxazine derivatives. New J Chem. 2019;43(26):10305-17.
21. Alaa AM, El-Azab AS, Abou-Zeid LA, et al. Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: molecular docking studies. Eur J Med Chem. 2016;115:121-31.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Prasad Mettikolla
Independent Researcher, A&P Pharmacy INC, 207 E Byron Nelson Blvd, Roanoke, TX-76224, USA.
Dr. T. Sunil Kumar Reddy
Rajputana College of Pharmacy, 1 Lake View Street, Coffee Board Layout, Nagavara, Bengaluru - 560024, Karnataka.
Dr. G. Balammal
Rajputana College of Pharmacy, 1 Lake View Street, Coffee Board Layout, Nagavara, Bengaluru - 560024, Karnataka.